Oneness Biotech

4743.TWO

3.17 USD

-0.06

-1.86%

Overview

Last close

3.17 usd

Market cap

1.52B usd

52 week high

7.13 usd

52 week low

3.12 usd

Target price

7.18 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

442.5879

Price/Book Value

3.8334

Enterprise Value

1.33B usd

EV/Revenue

571.633

EV/EBITDA

-91.0869

Key financials

Revenue TTM

3.44M usd

Gross Profit TTM

25.90M usd

EBITDA TTM

-21.33M usd

Earnings per Share

-0.1 usd

Dividend

N/A usd

Total assets

14.76B usd

Net debt

-413.79M usd

About

Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation segments. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials. It is also developing FB825, which is in Phase IIa clinical trial for treating atopic dermatitis and allergic asthma; FB704A that has completed Phase I clinical trial for the treatment of rheumatoid arthritis; OB318, an anticancer botanical drug of antrodia cinnamomea; SNS812, for the treatment of COVID-19 that is in Phase I clinical trials; and FB918 for the treatment of asthma. In addition, the company engages in the management of agriculture cultivation and trading business; and production and sale of agricultural products. Oneness Biotech Co., Ltd. was incorporated in 2008 and is headquartered in Taipei, Taiwan.